Shares of Novo Nordisk surged over 4% in early Friday pre-market trading, driven by positive news in the pharmaceutical sector. The increase follows Eli Lilly's Phase 3 trial results for their obesity drug, which lag behind Novo Nordisk’s semaglutide. Investors reacted to the competitive landscape, boosting Novo Nordisk’s stock as confidence in their obesity and diabetes treatments remains strong. The video provides insights into market movements and the factors influencing stock performance today.